Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
University of Florida
National Cancer Institute (NCI)
BeOne Medicines
BeOne Medicines
National Cancer Institute (NCI)
Aptarion Biotech AG
AstraZeneca
National Cancer Institute (NCI)
Pharmacyclics LLC.
National Cancer Institute (NCI)
MEI Pharma, Inc.
National Cancer Institute (NCI)
Medtronic Cardiovascular
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
SWOG Cancer Research Network
Nurix Therapeutics, Inc.
Dana-Farber Cancer Institute
Massachusetts General Hospital
Galapagos NV
Pfizer
University of Washington
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center
Janssen Research & Development, LLC
Masonic Cancer Center, University of Minnesota
Merck Sharp & Dohme LLC
BeOne Medicines
M.D. Anderson Cancer Center
University of Chicago
Regeneron Pharmaceuticals
M.D. Anderson Cancer Center
Sichuan Huiyu Pharmaceutical Co., Ltd
Regeneron Pharmaceuticals
Novartis
University of Washington
Nuvation Bio Inc.
University of Cincinnati
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
University of Wisconsin, Madison
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Genmab
Genmab
Cho Pharma Inc.
Genmab
ModeX Therapeutics, An OPKO Health Company
Allogene Therapeutics
Indiana University